Ideaya Biosciences Stock News

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -51.61% and 70.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

Stifel has upgraded Ideaya Biosciences (IDYA) to buy from hold as the risk/reward for its lead candidate IDE397 has improved and the stock is down recently.

Upgrades For Alpha Metallurgical Resources Inc (NYSE: AMR ), B. Riley Securities upgraded the previous rating of Neutral to Buy. For the fourth quarter, Alpha Metallurgical had an EPS of $13.30, compared to year-ago quarter EPS of $3.00. At the moment, the stock has a 52-week-high of $132.70 and a 52-week-low of $11.13. Alpha Metallurgical closed at $121.64 at the end of the last trading period. For Hormel Foods Corp (NYSE: HRL ), Argus Research upgraded the previous rating of Hold to Buy. In the first quarter, Hormel Foods showed an EPS of $0.44, compared to $0.41 from the year-ago quarter. The stock has a 52-week-high of $53.19 and a 52-week-low of $40.48. At the end of the last trading period, Hormel Foods closed at $49.91. According to Wells Fargo, the prior rating for Arista Networks Inc (NYSE: ANET ) was changed from Equal-Weight to Overweight. In the fourth quarter, Arista Networks showed an EPS of $0.82, compared to $0.62 from the year-ago quarter. At the moment, the stock has a 52-week-high of $536.54 and a 52-week-low of $108.23.

GlaxoSmithKline PLC found using ticker (GSK) have now 2 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 51.5 and 45.64 with a mean TP of 48.57. With the stocks previous close at 41.86 this now indicates there is a potential upside of 16.0%. The 50 day MA is 44.16 and the 200 day MA is 41.31. The company has a market capitalisation of $105,612m. You can visit the company''s website by visiting: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets=GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $122,541m based on the market concensus. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.

SOUTH SAN FRANCISCO, Calif., March 1, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and de

Steven Cohen (Trades, Portfolio), leader of Point72 Asset Management, disclosed earlier this week he increased his stake in IDEAYA Biosciences Inc. ( IDYA , Financial) by 52.12%.

SOUTH SAN FRANCISCO, Calif., Feb. 1, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and dev

Gainers: Puma Biotechnology PBYI +16%, Marin Software (MRIN) +9%, Midland States Bancorp (MSBI) +6%, IDEAYA Biosciences (IDYA) +3%, Ironwood Pharmaceuticals (IRWD) +3%.Losers:…

Ideaya Biosciences Inc (IDYA) shares closed this week 20.0% lower than it did at the end of last week. The stock is currently down 24.5% year-to-date, up 19.6% over the past 12 months, and up 59.4% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Shares traded as high as $22.48 and as low as $16.75 this week.Shares closed 36.3% below its 52-week high and 16.9% above its 52-week low.Trading volume this week was 24.1% higher than the 10-day average and 15.7% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1601.1% The company's stock price performance over the past 12 months beats the peer average by -217.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SOUTH SAN FRANCISCO, Calif., Jan. 3, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and dev

IDEAYA Biosciences (NASDAQ:IDYA) had its price objective raised by research analysts at Roth Capital from $38.00 to $42.00 in a research note issued to investors on Wednesday, The Fly reports. The firm presently has a buy rating on the stock. Roth Capitals target price would suggest a potential upside of 89.19% from the companys current []

Analysts predict that IDEAYA Biosciences, Inc. (NASDAQ:IDYA) will announce sales of $10.13 million for the current quarter, Zacks reports. Six analysts have provided estimates for IDEAYA Biosciences earnings, with the highest sales estimate coming in at $15.00 million and the lowest estimate coming in at $7.00 million. IDEAYA Biosciences reported sales of $10.57 million in []

Redmond Asset Management LLC lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 10.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,966 shares of the companys stock after acquiring an additional 1,112 shares during the quarter. Redmond Asset Management LLCs holdings in []

Ideaya Biosciences Inc (NASDAQ: IDYA ) provided a clinical data update for the Phase 1/2 trial evaluating darovasertib and

(RTTNews) - IDEAYA Biosciences, Inc. (IDYA) issued a clinical data update for the phase 1/2 trial evaluating darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma patients. The preliminary interim data includes: 100% disease control rate; ad 31% overall response rate. The company said these data provide clinical…